<DOC>
	<DOCNO>NCT02113722</DOCNO>
	<brief_summary>The purpose study determine whether incidence recurrent life threaten ventricular arrhythmia patient implanted cardiac defibrillator ( ICD ) reduce surgical left stellate ganglionectomy perform .</brief_summary>
	<brief_title>Is Left Stellate Ganglionectomy Beneficial Patients With Life Threatening Ventricular Arrhythmias</brief_title>
	<detailed_description>Background : Sudden cardiac death ( SCD ) devastate problem . There strong body evidence suggest important role autonomic nervous system genesis sudden cardiac death . An increase vagal tone improve cardiac electrical stability whereas sympathetic hyper-stimulation may precipitate ventricular fibrillation , particularly ischaemic heart . In patient life threaten ventricular arrhythmia implant cardiac defibrillator ( ICD ) treatment choice . Ventricular arrhythmia terminate either intra-cardiac shock , often painful therapy particularly patient remain conscious , anti-tachycardia pacing ( ATP ) painless often unnoticed . Despite intensive pharmacological treatment beta-blockers often amiodarone , patient may still 20 % risk per year receive internal shock life threaten sometimes non life threaten arrhythmia . A technique might reduce risk shock delivery current approach would advantage . It suggest surgical left stellate ganglionectomy ( also refer leave cardiac sympathetic denervation - LCSD ) patient cardiac arrhythmia may potential antiarrhythmic benefit particularly patient life threaten ventricular arrhythmia and/or high risk sudden death ( SCD ) despite current medical therapy . Recent improvement surgical technique allow video assist minimal access approach ( VATS ) reduction inpatient stay increase patient tolerability . The overall risk profile open thoracotomy much reduce rate . Current data suggest LCSD reasonable management option patient recurrent ventricular arrhythmia . Hypothesis : Does VATS assist LCSD patient ICD implant secondary prevention , chronic amiodarone therapy reduce shock frequency anti-tachycardia pacing compare optimal medical treatment - prospective study . Protocol : All patient ICD present intra-cardiac shock ATP termination ventricular arrhythmia ( VT VF ) eligible study . All patient establish optimal medical treatment ( angiotensin-converting-enzyme ( ACE ) inhibitor/angiotensin receptor blocker ( ARB ) beta blocker ) amiodarone ( unless documentation exist amiodarone intolerance ) , three month , define inclusion criterion . Patients give Participant Information Sheet describe study sign Informed Consent obtain . Baseline test perform group . Patients randomise 1:1 fashion either continued medical treatment continue medical treatment plus minimal access video assist left stellate ganglionectomy . Surgery perform within two week randomisation . Surgical patient discharge hospital discretion treat surgeon . The surgical patient assess clinic two week discharge . All patient follow total 365 day randomisation . Primary Endpoint : • Intra-cardiac shock frequency frequency anti-tachycardia pace 12 month period commence time randomisation minimum 365 day post-study entry . Secondary Endpoints : - All-cause mortality - Heart Failure hospital admission randomisation - Early late surgical complication - - death - Horner 's syndrome - length hospital stay - post-operative pain - sweating leave hand axilla - damage brachial plexus - Changes heart rate variability ( HRV ) - Inappropriate intra-cardiac shock atrial tachyarrhythmias : atrial fibrillation , flutter tachycardia - Changes leave ventricular function ( ejection fraction ) measure echocardiography - Changes heart-to-mediastinum ( H/M ) ratio iodine-131-meta-iodobenzineguanidine ( MIBG ) - Alterations surface twelve lead ECG include : - change QT interval - change QT dispersion surface ECG - change QRS duration - Changes ICD device derive parameter : - Frequency non-sustained ventricular tachycardia ventricular premature contraction - Changes heart rate variability - If appropriate ( ICD dependent ) change transthoracic impedance - Atrial fibrillation burden - Quality life assessment ( SF36 ) Sample Size Sample size base upon project 10 % shock rate first 12 month mortality 5-8 % ( 1,2,3 ) . As pilot study sample 25 patient group ( medical treatment alone vs. LCSD ) .</detailed_description>
	<mesh_term>Death</mesh_term>
	<mesh_term>Death , Sudden , Cardiac</mesh_term>
	<criteria>Age 18yrs old old . Medical indication ICD secondary prevention per standard ESC/ACC guideline . Patients single , dual chamber biventricular defibrillator ( CRTD ) include . Intracardiac shock ATP VT VF : For study inclusion patient must recent intracardiac shock ATP ( ≤30 day ) . For study inclusion patient must optimise amiodarone therapy ( ≥3 month ) document evidence amiodarone intolerance . For study inclusion Intracardiac shock ATP VT VF must secondary reversible biochemical drug induce arrhythmia . Ejection fraction ≤ 40 % measure ≤ 6 month prior Baseline Visit . Surgical review ensure patient suitable surgery . Women childbearing potential must negative pregnancy test . Written informed consent . Age less 18years . Pregnancy . Predicted life expectancy le one year . Intracardiac shock ATP VT VF secondary reversible biochemical drug induce arrhythmia . Severe renal impairment estimate glomerular filtration rate ( eGFR ) less 20mL/mins . Unsuitable cardiac surgery . Nonoptimised heart failure medication ( ACE inhibitors/ARB blocker and/or betablockers ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Sudden cardiac death</keyword>
	<keyword>Ganglionectomy</keyword>
	<keyword>Ventricular arrhythmia</keyword>
	<keyword>Cardiac surgery</keyword>
	<keyword>Implanted cardiac defibrillator</keyword>
</DOC>